In a report published Friday, Jefferies reiterated its Buy rating on Medidata Solutions MDSO, and raised its price target from $48.50 to $59.00.
Jefferies noted, “Medidata's emergence as a SaaS leader is progressing rapidly. The company continues to win market share, expand its footprint within existing clients, and upsell high-margin modules. Similar to other SaaS stocks in our coverage list, investors are intently focused on revenue currently. This enables management to aggressively reinvest in the business to continue driving 20% revenue growth. MDSO is still early in its growth ramp.”
Medidata Solutions closed on Thursday at $50.79.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in